[1]杜文婷,何 雨,吴 越,等.对比立体定向放射治疗与射频消融治疗肝细胞癌效果的Meta分析[J].介入放射学杂志,2023,32(12):1233-1241.
 DU Wenting,HE Yu,WU Yue,et al.Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a meta-analysis[J].journal interventional radiology,2023,32(12):1233-1241.
点击复制

对比立体定向放射治疗与射频消融治疗肝细胞癌效果的Meta分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年12
页码:
1233-1241
栏目:
临床研究
出版日期:
2024-01-02

文章信息/Info

Title:
Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a meta-analysis
作者:
杜文婷 何 雨 吴 越 郁冰心 鲁 杨 林元强 战翠萍 金春香
Author(s):
DU Wenting HE Yu WU Yue YU Bingxin LU Yang LIN Yuanqiang ZHAN Cuiping JIN Chunxiang.
Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province 130033, China
关键词:
【关键词】 立体定向放射治疗 射频消融 肝细胞癌 Meta分析
文献标志码:
A
摘要:
【摘要】 目的 全面收集国内外立体定向放射治疗(SBRT)和射频消融(RFA)治疗肝细胞癌(HCC)相关研究文献,通过Meta分析系统比较这两种治疗方法的临床效果及相关并发症。方法 计算机检索PubMed、Embase、Cochrane Library、Scopus、Web of Science以及中国生物医学文献(CBM)、知网、万方、维普等中英文数据库自建库至2022年6月发表的SBRT和RFA临床治疗HCC文献。采用Stata 14.0软件进行Meta分析。 结果 共纳入14项回顾性研究6 806例患者。基于总生存期(OS)的综合风险比(HR)结果显示SBRT术后OS低于RFA术后(HR=1.25,95%CI=1.10~1.43,I2=0%,P=0.000 9),而局部控制(LC)比率的综合HR显示SBRT有更好的疗效(HR=0.61,95%CI=0.47~0.78,I2=0%,P=0.000 1)。亚组分析显示,LC比率的综合HR更支持对肿瘤直径>2 cm患者行SBRT(HR=2.64,95%CI=1.56~4.48,I2=0%,P=0.000 3)。SBRT组与RFA组间晚期严重不良反应发生率差异无统计学意义(OR=1.01,95%CI=0.59~1.73,I2=30%,P=0.97)。结论 SBRT与RFA相比虽未表现出生存获益上的优势,但在HCC局部控制方面表现出较优的效果,尤其是对肿瘤直径>2 cm的患者。

参考文献/References:

[1] Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20: 3100-3111.
[2] Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials[J]. Onco Targets Ther, 2018, 11: 2865-2874.
[3] 朱诗迪,郑 琳. 经皮穿刺热消融术在肝细胞癌中的临床应用进展[J]. 介入放射学, 2022, 31:1224-1227.
[4] Jeong Y, Jung J, Cho B, et al. Stereotactic body radiation therapy using a respiratory- gated volumetric- modulated arc therapy technique for small hepatocellular carcinoma[J]. BMC Cancer, 2018, 18: 416.
[5] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time- to- event data into meta- analysis[J]. Trials, 2007, 8: 16.
[6] Ji R,Ng KK,Chen W,et al. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma[J]. Medicine(Baltimore), 2022, 101: e28545.
[7] Ueno M, Takabatake H, Itasaka S, et al. Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma: a propensity- score matching analysis of their impact on liver function and clinical outcomes[J]. J Gastrointest Oncol, 2021, 12: 2334-2344.
[8] Jeong Y,Lee KJ,Lee SJ,et al. Radiofrequency ablation versus stereotactic body radiation therapy for small(≤3 cm)hepatocellular carcinoma: a retrospective comparison analysis[J]. J Gastroenterol Hepatol, 2021, 36: 1962-1970.
[9] Kim N, Kim HJ, Won JY, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma[J]. Radiother Oncol, 2019, 131: 81-87.
[10] Pan YX, Xi M, Fu YZ, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study[J]. Cancers (Basel), 2019, 11: 1116.
[11] Jackson WC, Tao Y, Mendiratta-Lala M, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases[J]. Int J Radiat Oncol Biol Phys, 2018, 100: 950-958.
[12] Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database[J]. J Clin Oncol, 2018, 36: 600-608.
[13] 张 弢,谢 辉,孙 静,等. 立体定向放射治疗与射频消融治疗肝癌的临床对比研究[J]. 传染病信息, 2016, 29:215-222.
[14] Wahl DR,Stenmark MH,Tao Y,et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J]. J Clin Oncol, 2016, 34: 452-459.
[15] 肖金成,郭雷鸣,康鑫鑫,等. 射频消融术与立体定向放射治疗原发性小肝癌的临床效果比较[J]. 肿瘤防治研究, 2017, 44:831- 835.
[16] 杨 曌,谢 辉,王 权,等. 射波刀与射频消融治疗小肝癌的近期效果比较[J]. 临床肝胆病杂志, 2019, 35:1965-1969.
[17] Hara K,Takeda A,Tsurugai Y,et al. Radiotherapy for hepato-cellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis[J]. Hepatology, 2019, 69: 2533-2545.
[18] Parikh ND, Marshall VD, Green M, et al. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early- stage hepatocellular carcinoma: an analysis of SEER-medicare[J]. J Med Imaging Radiat Oncol, 2018, 62: 673- 681.
[19] Shiozawa K, Watanabe M, Ikehara T, et al. Comparison of percutaneous radiofrequency ablation and CyberKnife?誖 for initial solitary hepatocellular carcinoma: a pilot study[J]. World J Gastroenterol, 2015, 21: 13490-13499.
[20] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67: 358-380.
[21] Doyle A,Gorgen A,Muaddi H,et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients[J]. J Hepatol, 2019, 70: 866-873.
[22] Xue J, Ni H, Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy[J]. J Interv Med, 2021, 4: 105-113.
[23] 陈 磊,陈 诗,郑传胜. 肝癌放射治疗研究进展[J]. 介入放射学, 2020, 29:631- 635.
[24] Forner A,Reig M,Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391: 1301-1314.
[25] Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19: 541-565.
[26] Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma[J]. Semin Radiat Oncol, 2017, 27: 247-255.
[27] Dobrzycka M, Spychalski P, Rostkowska O, et al. Stereotactic body radiation therapy for early- stage hepatocellular carcinoma: a systematic review on outcome[J]. Acta Oncol (Madr), 2019, 58: 1706-1713.
[28] Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma[J]. Radiation Oncology, 2013, 8: 250.

相似文献/References:

[1]蒲红.上海市第二届射频消融疑难病例研讨会纪要[J].介入放射学杂志,1997,(01):63.
[2]蒲红,尹炯,王咏梅,等.显性间隔房室旁路的射频消融[J].介入放射学杂志,1997,(02):104.
[3]罗荣光,黄金华.肿瘤射频消融:电极的类型和消融灶的特点[J].介入放射学杂志,2011,(02):159.
 LUO Rong-guang,HUANG Jin-hua..Radiofrequency ablation of tumors: the relationship between the electrode type and the feature of ablated zone[J].journal interventional radiology,2011,(12):159.
[4]程洪涛,郭晨阳,黎海亮,等.TACE联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
 ,,et al.TACE combined with CTguided percutaneous radiofrequency ablation for the treatment of primary hepatocellular carcinomas: an analysis of factors affecting the therapeutic result [J].journal interventional radiology,2012,(12):216.
[5]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合CT引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
 ,,et al.Sequential treatment with TACE and CTguided RFA for small and moderate sized HCC [J].journal interventional radiology,2012,(12):301.
[6]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗30例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
 ,,et al.TACE combined with radiofrequency ablation for massive primary hepatocellular carcinomas: a clinical therapeutic evaluation [J].journal interventional radiology,2012,(12):322.
[7]朱先海,吕维富,鲁 东,等.超选择性肾动脉栓塞术联合射频消融治疗肾癌的临床应用[J].介入放射学杂志,2011,(07):541.
 ZHU Xian-hai,LV Wei-fu,LU Dong,et al.Superselective renal artery embolization combined with radiofrequency ablation for the treatment of renal carcinomas: evaluation of clinical results[J].journal interventional radiology,2011,(12):541.
[8]谢小西,吕银祥,章宏欣,等. 肝动脉化疗栓塞、射频消融联合125Ⅰ粒子植入 治疗原发性肝癌的临床应用[J].介入放射学杂志,2011,(11):863.
 XIE Xiao-xi,LV Yin-xiang,ZHANG Hong-xin,et al.The clinical application of TACE together with RFA and 125Ⅰ seed implantation in treating hepatocellular carcinoma[J].journal interventional radiology,2011,(12):863.
[9]李建军,郑加生,崔雄伟,等. 肝肿瘤CT引导经皮射频消融术后胆道并发症防治[J].介入放射学杂志,2011,(12):984.
 LI Jian-jun,ZHENG Jia-sheng,CUI Xiong-wei,et al.The prevention and treatment of biliary complications occurred after CT-guided percutaneous radiofrequency ablation for hepatic neoplasms[J].journal interventional radiology,2011,(12):984.
[10]陈万海,朱晓黎.射频消融联合无水乙醇注射在兔肝脏中的实验研究[J].介入放射学杂志,2012,(12):1015.
 CHEN Wan? hai,ZHU Xiao? li.. Combined use of radiofrequency ablation and percutaneous ethanol injection for liver tissue: an in vivo experimental study in rabbits[J].journal interventional radiology,2012,(12):1015.

备注/Memo

备注/Memo:
(收稿日期:2022-12-28)
(本文编辑:谷 珂)
更新日期/Last Update: 2024-01-02